Ordering Recommendation

Aids in the workup of suspected myeloproliferative neoplasms. Use to detect the JAK2 V617F mutation in peripheral blood or bone marrow.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Whole blood or bone marrow in lavender (EDTA). Also acceptable: Whole blood in green (sodium heparin).

Specimen Preparation

Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma, serum, FFPE tissue blocks/slides, or fresh or frozen tissue. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.

Remarks
Stability

Refrigerated: 7 days; Frozen: Unacceptable

Methodology

Droplet Digital PCR (ddPCR)

Performed

Varies

Reported

2-9 days

Reference Interval

Interpretive Data

Refer to report. 

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81270

Components

Component Test Code* Component Chart Name LOINC
3003752 JAK2 QNT, Source 31208-2
3003753 JAK2 V617F Percent Mutated Alleles 53761-3
3003754 JAK2 V617F Mutation by PCR 43399-5
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • BCR-ABL1 negative testing
  • Classic BCR-ABL1-negative testing
  • MPN JAK2
  • mutant JAK2 V617F allelic burden
JAK2 (V617F) Mutation by ddPCR, Quantitative